ORIC Pharmaceuticals, Inc. (ORIC) SEC Filings & Earnings Calls

Clinical trial risks and regulatory uncertainties remain; forward-looking statements highlight potential changes in outcomes as more data becomes available.

“Forward-looking statements caution that clinical outcomes may materially change as patient enrollment continues or more patient data becomes available.”

Clinical trial failure risk

“The successful development of our product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our product candidates.” · word for word

Financing risk

“If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives.” · word for word

Dependence on key programs

“On August 12, 2025, the Company announced a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, rinzimetostat and enozertinib. This initiative resulted in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research” · word for word

Clinical development risk; Phase 3 trial outcomes uncertain; regulatory approval not guaranteed.

“Initiated Himalayas-1 global Phase 3 registrational trial; primary endpoint radiographic progression-free survival”

Potential dilution from increased share reserve for inducement awards

“Additional 1,100,000 shares reserved for equity awards; total 3,350,000 shares reserved under Inducement Plan.”

Potential shareholder dilution from increased equity awards; plan amendments approved by stockholders.

“Stockholders approved the A&R 2020 Equity Incentive Plan with 61.2M votes for, 27.3M against.”

Clinical trial failure risk

“The successful development of our product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our product candidates.” · word for word

Cash burn and going concern risk

“If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives.” · word for word

Clinical stage company with no revenue; dependent on pipeline success and financing.

“Clinical stage oncology company; no revenue reported; cash burn from R&D.”

R&D expenses increased 27.6% YoY, indicating higher cash burn rate.

“R&D expenses were $31.4 million ... compared to $24.6 million ... an increase of $6.8 million.” · word for word

Clinical-stage biotech with no approved products; reliance on pipeline success.

“Clinical stage oncology company ... no revenue from product sales disclosed.”

No approved products or revenue

“We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever.” · word for word

Substantial dependence on two product candidates

“We are substantially dependent on the success of our product candidates, rinzimetostat and enozertinib.” · word for word

Clinical trial failure risk

“A failure of one or more clinical trials can occur at any stage of the process.” · word for word

Dilution risk from ongoing ATM sales

“Company has sold 13.5M shares and may sell up to $200M more, diluting existing shareholders.”

Clinical development risk; early-stage data.

“Phase 1b trial data; no registrational milestones.”

Early-stage clinical data; no regulatory approvals

“Phase 1b trial data; forward-looking statements about potential best-in-class properties”

Pre-revenue clinical-stage company; no approved products

“clinical stage oncology company ... no revenue from product sales”

Clinical trial risks for ORIC-944 and enozertinib

“Phase 1b trials; forward-looking statements about potential best-in-class properties”

Clinical Trial Risk

“The successful development of our product candidates is highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our product candidates.” · word for word

Financing Risk

“As the Company continues its expansion, it may seek additional financing and/or strategic investments, however, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all.” · word for word